RARE DISEASE
Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria
Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria
Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria
Synonyms: BH4-responsive HPA/PKU, BH4-responsive hyperphenylalaninemia/phenylketonuria, Tetrahydrobiopterin-responsive HPA/PKU
Synonyms: BH4-responsive HPA/PKU, BH4-responsive hyperphenylalaninemia/phenylketonuria, Tetrahydrobiopterin-responsive HPA/PKU
Synonyms: BH4-responsive HPA/PKU, BH4-responsive hyperphenylalaninemia/phenylketonuria, Tetrahydrobiopterin-responsive HPA/PKU
Drug discovery
2
drugs
With orphan designations
Overview
Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria (BH4-responsive PKU) is a subset of PKU caused by specific PAH gene mutations that retain residual phenylalanine hydroxylase activity. Oral BH4 supplementation stabilizes the mutant enzyme, lowering blood phenylalanine (Phe) by >30% in responders [1][8]. Up to 58% of PKU patients may benefit, reducing reliance on strict Phe-restricted diets while maintaining metabolic control [1][4][9].
Burden
Lifelong management risks neuropsychiatric comorbidities (anxiety, depression) and cognitive deficits, even with treatment [5][6].
Strict dietary compliance remains challenging, with 35–45% of adults failing to meet Phe targets [7][9]. BH4-responsive patients face reduced nutritional deficiencies and psychosocial stress compared to classical PKU [6][7].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases
Research Papers
163 drug discovery papers about Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
163 drug discovery papers about Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-07 | Sapropterin (BH4) challenge in phenylketonuria: Responder or non-responder?
Sapropterin dihydrochloride, the synthetic form of tetrahydrobiopterin (BH4), is an established pharmacological treatment for a subset of patients with phenylalanine hydroxylase (PAH) deficiency. Yet the clinically simple question of whether a patient is a "responder" or "non-responder" remains difficult to answer in a uniform way. Since the first description of BH4-responsive PAH deficiency, challenge protocols have varied substantially, ranging from short 4-8 h loading tests to 24-48 h protocols, 72 h to 7-day approaches, and treatment trials lasting several weeks or months. These protocols differ in dose, duration, sampling schedule, dietary conditions, baseline phenylalanine (Phe) concentration, use of Phe loading, and response definition. European, American, and Japanese guidance also differ in target ranges and in how responsiveness is confirmed. The widely used criterion of at least 30% reduction in blood Phe is practical for short biochemical testing, but it may be insufficient in patients who are already well controlled on diet, in slow responders, in infants or preschool children in whom BH4 bioavailability may be lower, and in patients whose main benefit is increased daily dietary Phe tolerance rather than further Phe reduction. Recent European guidance distinguishes potential sapropterin responsiveness from long-term responsiveness, defining the latter by increased natural protein intake and/or improved biochemical control within the recommended therapeutic target range. Japanese guidance adds an important Asian perspective by recommending BH4 administration tests for all hyperphenylalaninemia/phenylketonuria (PKU) cases rather than relying only on phenotype or blood Phe level, and recent Japanese data suggest that age and baseline Phe may influence blood biopterin peaks and the risk of false-negative tests. This narrative review summarizes the historical development, biological rationale, clinical evidence, geographical variation, genotype-specific considerations, and practical limitations of BH4/sapropterin responsiveness testing in PKU. We propose a pragmatic responder/non-responder framework based on three linked dimensions: blood Phe reduction, increase in daily dietary Phe tolerance, and maintenance of blood Phe within age-, pregnancy-, and guideline-specific therapeutic ranges. A responder is best defined as a patient who demonstrates either reproducible biochemical response or clinically meaningful therapeutic benefit, while a non-responder is a patient who demonstrates neither under adequate testing conditions. Evidence from extended Dutch testing further supports using 7-day protocols selectively when 48 h results are borderline or clinically discordant, while avoiding a simple 20% threshold because of false-positive risk.
2026-02-21 | Genotype–phenotype correlations in phenylketonuria: PAH variants and BH4 responsiveness for treatment design
BACKGROUND: Phenylketonuria (PKU) is an autosomal recessive disorder caused by PAH alterations, leading to elevated phenylalanine (Phe) and neurotoxicity. Newborn screening (NBS) and early therapy improve outcomes. This study aimed to characterize the molecular and phenotypic spectrum of PKU, explore genotype–phenotype correlations, and evaluate the relationship between PAH variants and BH4 responsiveness to guide personalized treatment. METHODS: Medical and genetic records of 171 patients diagnosed with hyperphenylalaninemia via NBS were reviewed. Demographic data, diagnostic Phe and tyrosine (Tyr) levels, BH4 loading test results, and genetic analyses including Sanger sequencing, MLPA, and array CGH were assessed. Allelic and genotype–phenotype values were used to estimate variant severity. RESULTS: 168 carried ≥ 1 PAH variant; three had BH4 metabolism disorders. A total of 63 distinct PAH variants were identified; MLPA detected large deletions in three patients. Five variants (c.1066-11G > A, c.782G > A, c.143T > C, c.898G > T, c.1208 C > T) accounted for > 50% of the cohort. Among 100 patients tested, 41% responded to BH4, with c.782G > A most common (21%). Overall, 68.5% received dietary and/or BH4 therapy. CONCLUSION: This study contributes to our understanding of PKU’s molecular and phenotypic landscape, highlighting the importance of utilising both genotype and response to the BH4 loading test in the design of personalised treatments, beyond the initial Phe level.
2025-09-07 | Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring
Background: Phenylketonuria (PKU) is a rare autosomal recessive metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to hyperphenylalaninemia (HPA). Untreated, elevated phenylalanine (Phe) levels cause severe neurocognitive, developmental, and psychiatric complications. Management relies on a Phe-restricted diet, which is challenging to maintain, particularly in adolescents and adults. Sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4), can enhance residual PAH activity, lowering blood Phe levels and increasing dietary tolerance in responsive patients. However, real-world alignment with best practices remains underexplored. This study aims to report a tertiary referral center's experience with sapropterin treatment in PKU and assess adherence to international guidelines. Methods: We retrospectively analyzed 23 PKU patients treated with sapropterin from 2007 to 2025. Patients with baseline Phe levels of 360-2000 µmol/L underwent a 10 mg/kg/day loading test over two weeks. Responsiveness was defined as a ≥30% reduction in blood Phe levels. Phe levels were measured pre- and post-test, and dietary tolerance was evaluated. Adherence to best practices was critically reviewed. Results: All patients showed significant Phe reductions (mean 71.43%, p < 0.0001), exceeding responsiveness thresholds. Most achieved substantial increases in dietary Phe tolerance, with three patients partially responsive (800-1200 mg/day). Responsiveness was unrespectful of the patient's genotype, for those individuals for whom this was known (8/23 patients). Although effective, the test dose and duration differed from guideline recommendations (20 mg/kg/day). Neuropsychological and QoL assessments were not systematically performed, representing a key limitation. Conclusions: Sapropterin dihydrochloride effectively identified responders and improved dietary flexibility even with lower dosing protocols. Greater adherence to international standards, particularly regarding long-term neuropsychological monitoring, is needed to optimize patient care.
2025-04-24 | Sepiapterin for the treatment of phenylketonuria
Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Untreated, PKU may result in severe and irreversible intellectual impairment due to marked hyperphenylalaninemia (HPA). Guidelines recommend lifelong reduction in Phe levels, usually achieved via a strict low-protein diet and sometimes medications. We discuss the role of tetrahydrobiopterin (BH4), an essential PAH cofactor in Phe metabolism, describe the pharmacodynamics, pharmacokinetics, and metabolism of sepiapterin, as well as reporting on the efficacy and safety of sepiapterin in children and adults with PKU. Sepiapterin, an oral synthetic form of a natural precursor of BH4, can reduce HPA in some patients with PKU. In relatively short-term studies, sepiapterin has been shown to be safe, well tolerated, and like the BH4 analog sapropterin dihydrochloride effectively reduces blood Phe levels in responsive individuals. The reductions in blood Phe observed with sepiapterin in the phase III APHENITY trial has the potential to allow more PKU patients to attain Phe treatment targets or alternatively easing of the onerous dietary Phe restrictions. Results of longer-term studies of in patients with PKU, including neurocognitive and functional outcomes, nutritional status, and quality of life are awaited.
2024-04-02 | Children and Adolescents with Early Treated Phenylketonuria: Cognitive Development and Fluctuations of Blood Phenylalanine Levels
Background: We assessed the relationship between the cognitive development of children and adolescents with phenylketonuria (PKU) and fluctuations in peripheral phenylalanine (Phe) levels. Methods: We examined the neurocognitive performance of 33 children and adolescents with early treated PKU, of whom 18 were treated with sapropterin dihydrochloride, and 15 were on a classic diet. For 26 weeks, patients were assessed weekly for their blood phenylalanine (Phe) levels. Phe levels were analyzed for fluctuations indicated by the individual standard deviation. Fluctuations were compared to the standard deviation of 26 Phe level measurements before the study interval. We also assessed the concurrent IQ of the patients. This was repeated at one-, two-, and seven-year intervals. Results: Full-scale IQ in patients treated with a classic diet did not change within the follow-up. In patients treated with Sapropterin dihydrochloride, however, there was a considerable gain in full-scale IQ. This was particularly true if blood Phe fluctuations increased in patients of this treatment group. Conclusions: Sapropterin dihydrochloride enhances Phe tolerance in patients with PKU. Increasing blood Phe fluctuations following enhanced Phe tolerance may indicate that the treatment not only allows patients to relax their Phe-restricted diet but also may support cognitive development in patients.
2026-08-07 | Sapropterin (BH4) challenge in phenylketonuria: Responder or non-responder?
Sapropterin dihydrochloride, the synthetic form of tetrahydrobiopterin (BH4), is an established pharmacological treatment for a subset of patients with phenylalanine hydroxylase (PAH) deficiency. Yet the clinically simple question of whether a patient is a "responder" or "non-responder" remains difficult to answer in a uniform way. Since the first description of BH4-responsive PAH deficiency, challenge protocols have varied substantially, ranging from short 4-8 h loading tests to 24-48 h protocols, 72 h to 7-day approaches, and treatment trials lasting several weeks or months. These protocols differ in dose, duration, sampling schedule, dietary conditions, baseline phenylalanine (Phe) concentration, use of Phe loading, and response definition. European, American, and Japanese guidance also differ in target ranges and in how responsiveness is confirmed. The widely used criterion of at least 30% reduction in blood Phe is practical for short biochemical testing, but it may be insufficient in patients who are already well controlled on diet, in slow responders, in infants or preschool children in whom BH4 bioavailability may be lower, and in patients whose main benefit is increased daily dietary Phe tolerance rather than further Phe reduction. Recent European guidance distinguishes potential sapropterin responsiveness from long-term responsiveness, defining the latter by increased natural protein intake and/or improved biochemical control within the recommended therapeutic target range. Japanese guidance adds an important Asian perspective by recommending BH4 administration tests for all hyperphenylalaninemia/phenylketonuria (PKU) cases rather than relying only on phenotype or blood Phe level, and recent Japanese data suggest that age and baseline Phe may influence blood biopterin peaks and the risk of false-negative tests. This narrative review summarizes the historical development, biological rationale, clinical evidence, geographical variation, genotype-specific considerations, and practical limitations of BH4/sapropterin responsiveness testing in PKU. We propose a pragmatic responder/non-responder framework based on three linked dimensions: blood Phe reduction, increase in daily dietary Phe tolerance, and maintenance of blood Phe within age-, pregnancy-, and guideline-specific therapeutic ranges. A responder is best defined as a patient who demonstrates either reproducible biochemical response or clinically meaningful therapeutic benefit, while a non-responder is a patient who demonstrates neither under adequate testing conditions. Evidence from extended Dutch testing further supports using 7-day protocols selectively when 48 h results are borderline or clinically discordant, while avoiding a simple 20% threshold because of false-positive risk.
2026-02-21 | Genotype–phenotype correlations in phenylketonuria: PAH variants and BH4 responsiveness for treatment design
BACKGROUND: Phenylketonuria (PKU) is an autosomal recessive disorder caused by PAH alterations, leading to elevated phenylalanine (Phe) and neurotoxicity. Newborn screening (NBS) and early therapy improve outcomes. This study aimed to characterize the molecular and phenotypic spectrum of PKU, explore genotype–phenotype correlations, and evaluate the relationship between PAH variants and BH4 responsiveness to guide personalized treatment. METHODS: Medical and genetic records of 171 patients diagnosed with hyperphenylalaninemia via NBS were reviewed. Demographic data, diagnostic Phe and tyrosine (Tyr) levels, BH4 loading test results, and genetic analyses including Sanger sequencing, MLPA, and array CGH were assessed. Allelic and genotype–phenotype values were used to estimate variant severity. RESULTS: 168 carried ≥ 1 PAH variant; three had BH4 metabolism disorders. A total of 63 distinct PAH variants were identified; MLPA detected large deletions in three patients. Five variants (c.1066-11G > A, c.782G > A, c.143T > C, c.898G > T, c.1208 C > T) accounted for > 50% of the cohort. Among 100 patients tested, 41% responded to BH4, with c.782G > A most common (21%). Overall, 68.5% received dietary and/or BH4 therapy. CONCLUSION: This study contributes to our understanding of PKU’s molecular and phenotypic landscape, highlighting the importance of utilising both genotype and response to the BH4 loading test in the design of personalised treatments, beyond the initial Phe level.
2025-09-07 | Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring
Background: Phenylketonuria (PKU) is a rare autosomal recessive metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to hyperphenylalaninemia (HPA). Untreated, elevated phenylalanine (Phe) levels cause severe neurocognitive, developmental, and psychiatric complications. Management relies on a Phe-restricted diet, which is challenging to maintain, particularly in adolescents and adults. Sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4), can enhance residual PAH activity, lowering blood Phe levels and increasing dietary tolerance in responsive patients. However, real-world alignment with best practices remains underexplored. This study aims to report a tertiary referral center's experience with sapropterin treatment in PKU and assess adherence to international guidelines. Methods: We retrospectively analyzed 23 PKU patients treated with sapropterin from 2007 to 2025. Patients with baseline Phe levels of 360-2000 µmol/L underwent a 10 mg/kg/day loading test over two weeks. Responsiveness was defined as a ≥30% reduction in blood Phe levels. Phe levels were measured pre- and post-test, and dietary tolerance was evaluated. Adherence to best practices was critically reviewed. Results: All patients showed significant Phe reductions (mean 71.43%, p < 0.0001), exceeding responsiveness thresholds. Most achieved substantial increases in dietary Phe tolerance, with three patients partially responsive (800-1200 mg/day). Responsiveness was unrespectful of the patient's genotype, for those individuals for whom this was known (8/23 patients). Although effective, the test dose and duration differed from guideline recommendations (20 mg/kg/day). Neuropsychological and QoL assessments were not systematically performed, representing a key limitation. Conclusions: Sapropterin dihydrochloride effectively identified responders and improved dietary flexibility even with lower dosing protocols. Greater adherence to international standards, particularly regarding long-term neuropsychological monitoring, is needed to optimize patient care.
2025-04-24 | Sepiapterin for the treatment of phenylketonuria
Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Untreated, PKU may result in severe and irreversible intellectual impairment due to marked hyperphenylalaninemia (HPA). Guidelines recommend lifelong reduction in Phe levels, usually achieved via a strict low-protein diet and sometimes medications. We discuss the role of tetrahydrobiopterin (BH4), an essential PAH cofactor in Phe metabolism, describe the pharmacodynamics, pharmacokinetics, and metabolism of sepiapterin, as well as reporting on the efficacy and safety of sepiapterin in children and adults with PKU. Sepiapterin, an oral synthetic form of a natural precursor of BH4, can reduce HPA in some patients with PKU. In relatively short-term studies, sepiapterin has been shown to be safe, well tolerated, and like the BH4 analog sapropterin dihydrochloride effectively reduces blood Phe levels in responsive individuals. The reductions in blood Phe observed with sepiapterin in the phase III APHENITY trial has the potential to allow more PKU patients to attain Phe treatment targets or alternatively easing of the onerous dietary Phe restrictions. Results of longer-term studies of in patients with PKU, including neurocognitive and functional outcomes, nutritional status, and quality of life are awaited.
2024-04-02 | Children and Adolescents with Early Treated Phenylketonuria: Cognitive Development and Fluctuations of Blood Phenylalanine Levels
Background: We assessed the relationship between the cognitive development of children and adolescents with phenylketonuria (PKU) and fluctuations in peripheral phenylalanine (Phe) levels. Methods: We examined the neurocognitive performance of 33 children and adolescents with early treated PKU, of whom 18 were treated with sapropterin dihydrochloride, and 15 were on a classic diet. For 26 weeks, patients were assessed weekly for their blood phenylalanine (Phe) levels. Phe levels were analyzed for fluctuations indicated by the individual standard deviation. Fluctuations were compared to the standard deviation of 26 Phe level measurements before the study interval. We also assessed the concurrent IQ of the patients. This was repeated at one-, two-, and seven-year intervals. Results: Full-scale IQ in patients treated with a classic diet did not change within the follow-up. In patients treated with Sapropterin dihydrochloride, however, there was a considerable gain in full-scale IQ. This was particularly true if blood Phe fluctuations increased in patients of this treatment group. Conclusions: Sapropterin dihydrochloride enhances Phe tolerance in patients with PKU. Increasing blood Phe fluctuations following enhanced Phe tolerance may indicate that the treatment not only allows patients to relax their Phe-restricted diet but also may support cognitive development in patients.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria, including 1 approved therapy.
2 orphan drug designations for Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase (S92G, H133M, I167K, L432I, V470A) and L-amino acid deaminase | cell therapies | EMA | 2023-04-21 | — | Orphix Consulting GmbH |
Pegylated recombinant phenylalanine ammonia lyase [Palynziq] | proteins | EMA | 2010-01-28 | 2019-05-08 | BioMarin International Limited |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.